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Since their introduction, array-based detection techniques have
flooded diagnostic practice worldwide. Technical innovation and
commercialization of array platforms have brought down their costs
and put them within reach of many diagnostic laboratories. Array
diagnostics are, therefore, rapidly replacing traditional karyotyping
techniques for a range of indications. Such innovations give rise
to many questions related to indications for testing, test outcome
interpretation, quality control, and the ethics of using arrays for
particular applications. There is a growing need for guidelines on
these topics. To address the key issues in this field, an international
workshop was organized in Amsterdam in 2011 under the auspices
of the Genetic Services Quality Committee of the European Soci-
ety of Human Genetics. The aim was to explore whether consensus
could be achieved on themajor quality issues and to produce recom-
mendations for the use of arrays to detect copy-number variations
(CNVs) in a diagnostic setting. The outcome of the workshop has
been summarized in five articles that formulate recommendations
and guidelines to cover the different aspects of CNV detection using
diagnostic arrays in genetics.
In general, it can be concluded that genome-wide array analy-
sis is well established in postnatal cytogenetics. Most commercially
available platforms and data analysis software packages are of high
quality and relatively easy to use. The article by Vermeesch et al.
(2012) aims to guide laboratories in assuring the quality of their
array experiments, by suggesting standards for the minimal resolu-
tion of the platform used, and for the interpretation and reporting
of the results. Unfortunately, the interpretation of CNVs is not al-
ways straightforward since the distinction between pathogenic and
benign variants can be difficult as, for example, CNVs with a highly
variable phenotype and incomplete penetrance are common. Web-
based databases, especially when used in combination, can be help-
ful in interpreting CNVs. A general clinical interpretation strategy
for CNVs is presented by de Leeuw et al. (2012). Because of the
genome-wide nature of the use of arrays, clinically relevant CNVs
will be detected that are not related to the patient’s known pheno-
type. This clearly raises ethical questions, which may be especially
complex if the tested individuals are children, investigated prena-
tally or postnatally.Dondorp et al. (2012) discuss these ethical issues,
trying to find a solution to possible “information overload” in coun-
seling, and exploring the balance between the “right to know” and
the “right not to know” in different situations.
Two particular clinical applications of array diagnostics are dis-
cussed in more detail. Vetro et al. (2012) explore the use of arrays
in prenatal diagnosis and provide recommendations for the various
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steps of the process, starting with pretest counseling. In their opin-
ion, arraydiagnostics have aplace in the caseof abnormalultrasound
findings as long as local guidelines have been established, whereas
the value of offering array diagnostics to all pregnant women is
highly debatable. Changing focus from constitutional to acquired
chromosomal abnormalities, Simons et al. (2012) review the clinical
value of array-based genome-wide screens in leukemia. The genetic
complexity of cancer cells requires the detection of small genomic
changes in a mixed cell population, as well as the ability to de-
tect regions of homozygosity. The authors discuss these technical
challenges and, again, stress the need for international data sharing.
We are proud to present this special collection of articles that re-
port on a set of recommendations and suggested guidelines for CNV
array diagnostics. They are meant to encourage further discussion,
development, and implementation of local, national, andpreferably,
international guidelines. The development of such guidelines will
not only be important for the use of array diagnostics as part of
good clinical and laboratory practice. There should be important
spin-off as well. In the rapidly changing landscape of genetic diag-
nostics, other genome-wide techniques are being introduced as well,
includingwhole-exome sequencing andwhole-genome sequencing.
Those who endeavor to apply these new technologies to standard
clinical use will likely face many challenges similar to those faced in
the routine application of array diagnostics.
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